ERBB2 and breast cancer: In conclusion, the present biomarker analysis of the BETH and KAITLIN RCTs supports the value of AMH in the diagnosis and prediction of POI in young women treated for breast cancer using modern chemotherapy regimens and anti-HER2 monoclonal antibodies.